Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy

Abstract

Aim. To study the levels of circulating microRNA-21 in patients with hypertrophic cardiomyopathy (HCM) of different ages. Materials and methods. The study included 49 patients with HCM. The proportion of females was 55.1%, males - 44.9%. The average age was 50 [32; 65] (from 19 to 86 years). The control group for microRNA-21 included 44 healthy individuals, respectively, matched by the age and sex with the studied patients. Patients was made in accordance with the recommendations of the European society of cardiology. Plasma microRNA expression was determined by PCR with reverse transcription and real-time detection of results. The relative level of gene expression was calculated in accordance with the standard procedure 2-ΔCt. results. Septal wall thickness at end diastole has a significant negative correlation with age in patients with HCM (r=-0.56; р<0.001). PWTd (posterior wall thickness at end diastole) has a significant positive correlation with age in patients with HCM (r=0.67, р<0.001). The level of circulating microRNA-21 in plasma is higher in patients with HCM compared to healthy individuals (5.28 [2.64; 13.96] and 0.84 [0.55; 1.23], respectively; p<0.001). Significantly higher levels of microRNA-21 were found in young patients aged from 19 to 45 years with the symptomatic course of HCM (36.76 [5.66; 42.22]) compared to patients with asymptomatic course <45 years of age (2.81 [1.45; 5.28]; p<0.002) and symptomatic patients 45 years (3.88 [2.16; 8.63]; p<0.002).) The calculated risk of SCD was significantly higher in young symptomatic patients with HCM (6.01 [3.64; 9.67]) compared to patients with asymptomatic course <45 years (2.41 [1.21; 3.89]; p<0.001) and symptomatic patients 45 years (2.56 [1.67; 4.41]; p<0.001). conclusion. The level of circulating microRNA-21 is significantly in patients with HCM compared to control group. The maximum level of circulating microRNA-21 was detected in patients with symptomatic course of HCM at the age of 45 years.